UX14; Prolato Clinical Research Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mandayam, Sreedhar
NCT03055598: Ferric Citrate in ESRD Pilot Project

Active, not recruiting
4
30
US
Ferric Citrate, Auryxia
Sreedhar Mandayam, Keryx Biopharmaceuticals
End Stage Renal Disease, Chronic Kidney Diseases
09/19
02/20
NCT04745910: Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Recruiting
4
10
US
Pegloticase, Des-(1-6)-(7-threonine,46-threonine,291-lysine,301-serine)uricase (EC 1.7.3.3, urate oxidase) Sus scrofa (pig) tetramer, Non Acetylated, Carbamates with alpha-carboxy-omega-methoxypoly(oxyethylene), Krystexxa, Methoxypolyethylene Glycol Uricase, Oxidase, Urate (Synthetic Sus scrofa variant pigks-DN subunit), homotetramer, amide with alpha-carboxy-omega-methoxypoly(oxy-1,2-ethanediyl), Polyethylene Glycol-uricase, Puricase, Rasburicase, Elitek, Recombinant Urate Oxidase, SR 29142, SR-29142, Urate Oxidase
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome
12/25
12/25
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
NEPTUNUS-2, NCT05349214 / 2021-005687-22: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
NCT04557462 / 2020-002200-40: A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Recruiting
3
500
Europe, Canada, Japan, US, RoW
LNP023, iptacopan
Novartis Pharmaceuticals, Novartis Pharma AG
Primary IgA Nephropathy
10/32
10/32
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Chinook Therapeutics, Inc.
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Terminated
N/A
715
Europe, Japan, US, RoW
THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence
Philip Morris Products S.A.
COPD, Smoking, Tobacco Use
09/24
09/24

Download Options